Marc A. Pfeffer

TL;DR: Based on the ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) study dealing with renal outcomes, Messerli as discussed by the authors concluded that albuminuria can no longer be regarded as a valid surrogate end point in renal disease and that dual renin-angiotensin

TL;DR: This paper proposes a simple, robust procedure based on a mixture population concept and provides a clinically meaningful group contrast summary for a well-defined target population and uses the data from a recent meta-analysis for evaluating statin therapies with respect to the incidence of fatal stroke events to illustrate the issues associated with the standard meta- analysis procedures.

TL;DR: The adaptation of the heart and vessels to hypertension, the clinical implications of these structural and functional changes, and the effects of therapy on cardiovascular function are reviewed.

TL;DR: In this article , the authors evaluated the relationship between atrial fibrillation and flutter (AFF) and outcomes, the treatment response to sacubitril/valsartan and first-detected AFF in patients with preserved ejection fraction (HFpEF) enrolled in the PARAGON-HF trial and found that history of AFF and AFF on ECG at enrollment was associated with higher risk of the primary outcome.

TL;DR: GDF-15 shows a robust and consistent independent association with CV death and HHF across all presentations of ASCVD, and its prognostic association with future myocardial infarction (MI) and stroke only remained significant in patients stabilized after recent ACS or with stable ASCVD.